Influence of cortisol, gonadal steroids and an energy deficit on biochemical indicators of bone turnover in Swine.
In the pig a high growth potential seems to favour a disposition for skeletal problems. Hormones of growth hormone (GH)/insulin-like growth factor (IGF)-I axis as well as cortisol and gonadal steroids are endocrine determinants of the anabolic potential but their effects on bone turnover in pigs have not been described. Thus, key hormones were either infused for 7 days (cortisol, 5alpha-dihydrotestosterone (DHT), oestradiol) or influenced by Metyrapone (inhibition of cortisol synthesis) or energy deficit (increasing GH). Each treatment was carried out in six growing barrows/treatment. Bone turnover was characterized by daily measurements indirect parameter of osteoblastic and osteoclastic activity, osteocalcin (OC) and tartrate-resistant acid phosphatase (TRAP) respectively. All treatments except cortisol infusion seemed to favour bone formation, as they led either to a pronounced increase in OC (Metyrapone: +14%) or to significantly reduced TRAP (DHT: -9%, E2: -17%, energy deficit: -25%) followed by significantly higher OC (DHT: +9%, E2: +6%, energy deficit: +18%). Cortisol infusion affected bone loss mainly by a severe inhibition of osteoblastic activity (OC: -61%). Some reactions are explained by direct effects of the infused gonadal steroids on bone cells (inhibition of osteoclasts) or of the experimentally modified cortisol levels (inhibition of osteoblasts by cortisol). Other effects seem to be mediated by concomitant changes of IGF-I (inhibition of osteoclasts after energy deficit or cortisol) and GH-secretion (increased osteoblastic activity during energy deficit), respectively. Consequences for co-ordinated bone turnover are discussed.
Weiler
U
U
Universität Hohenheim, Fachgebiet für Tierhaltung und Leistungsphysiologie (470), Garbenstr. 17, 70593 Stuttgart, Germany. weiler@uni-hohenheim.de
Finsler
S
S
Claus
R
R
D000135:Acid Phosphatase / Q000187:drug effects; D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology*; D001842:Bone and Bones / Q000187:drug effects*; D013196:Dihydrotestosterone / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D006854:Hydrocortisone / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000187:drug effects; D007527:Isoenzymes / Q000187:drug effects; D008297:Male; D008797:Metyrapone / Q000494:pharmacology*; D010006:Osteoblasts / Q000187:drug effects; D015675:Osteocalcin / Q000187:drug effects; D010010:Osteoclasts / Q000187:drug effects; D011897:Random Allocation; D013552:Swine / Q000378:metabolism*; D000071681:Tartrate-Resistant Acid Phosphatase
D000963:Antimetabolites; D007527:Isoenzymes; D013196:Dihydrotestosterone; D015675:Osteocalcin; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; D006854:Hydrocortisone; D008797:Metyrapone